jivana biotechnology inc is pleased to announce the addition of dr ajay maker to its advisory committee  prcom post profile for your business      submit press release join now     sign in   businesses articles press releases   business directory products  services jobs recent press releases press release pricing submit press release businesses products  services products services press releases jobs press release pricing  news by category  news by country  news by us region  recent news  prcom news on your site   press releases  jivana biotechnology inc press release share      blog receive press releases from jivana biotechnology inc by email pdf version rss feeds jivana biotechnology inc is pleased to announce the addition of dr ajay maker to its advisory committee dr maker brings surgical oncology experience with expertise in liver gallbladder colon pancreatic and other cancers to jivana biotechnologys advisory committee chicago il march   prcom jivana biotechnology inc is pleased to announce the addition of dr ajay maker to its advisory committeewe are thrilled with this addition to our advisory committee said sid hopps president and chief executive officer of jivana biotechnology the background and experience dr maker brings to jivana is invaluable as we move our cancer therapies into clinical development and shape our drug delivery strategies”dr maker is a surgical oncologist with board certification in general surgery his expertise includes treating benign and malignant diseases of the liver bile ducts gallbladder and pancreas as well as colon and other gastrointestinal cancers melanoma and sarcoma he joined the division of surgical oncology and the department of microbiology and immunology at the university of illinois at chicago after completing a fellowship in surgical oncology with a focus upon hepatopancreatobiliary surgery at memorial sloankettering cancer center and a fellowship in tumor immunology and surgical oncology at the national cancer institute dr maker cares for patients as part of a multidisciplinary team of medical oncologists radiation oncologists gastroenterologists and radiologists who specialize in treating patients with these specific cancersdr maker graduated from brown university with honors in fine arts and biology thereafter he enrolled in the yale school of medicine and was selected to enter the basic science research training fellowship where he was awarded the medical scholars award from the american diabetes association and the association for academic surgerynovartis research award upon entering the surgical residency training program at harvard university’s brigham and women’s hospital he had already chosen to pursue a career in surgical oncology and was accepted into the postdoctoral surgical oncology fellowship program under dr steven rosenberg in the surgery branch of the national cancer institute at the national institutes of health ncinih thereafter he went on to complete a surgical oncology fellowship at the memorial sloankettering cancer centerdr maker serves as a reviewer for multiple surgery and scientific journals and is a member of multiple academic and scientific societies including the society of surgical oncology’s gastrointestinal oncology working group the americas hepatopancreatobiliary association’s research committee and the association for academic surgery’s leadership committee he currently is director of surgical oncology for the creticos cancer center and director of surgical research for the university of illinois metropolitan group hospitals general surgery residency training program currently he serves as the principal investigator on a multiyear federal research grant from the national cancer institutenational institutes of health to study the immunobiology of gi cancersjivana biotechnology develops rna interference rnai therapeutics to treat a wide range of cancers including breast ovarian liver lung thyroid and pancreatic by down modulating a specific gene product that prevents programmed cell death rnai is a mechanism present in living cells that inhibits the expression of a specific gene affecting production of a specific protein jivana’s rnaibased therapeutics help leverage this natural pathway of gene silencing contact information jivana biotechnology incsidney hoppscontactwwwjivanabiotechcom click here to view the list of recent press releases from jivana biotechnology inc promote your business affiliate program link to us email this page to a friend prcom contact us about us terms of use help   jivana biotechnology inc announces additions to its advisory committee  prcom post profile for your business      submit press release join now     sign in   businesses articles press releases   business directory products  services jobs recent press releases press release pricing submit press release businesses products  services products services press releases jobs press release pricing  news by category  news by country  news by us region  recent news  prcom news on your site   press releases  jivana biotechnology inc press release share      blog receive press releases from jivana biotechnology inc by email pdf version rss feeds jivana biotechnology inc announces additions to its advisory committee jivana biotechnology adds patrick sage and dr frank facchini to its advisory committee chicago il april   prcom jivana biotechnology inc is pleased to announce the addition of patrick sage and dr frank facchini to its advisory committeewe are thrilled with this addition to our advisory committee said sid hopps president and chief executive officer of jivana biotechnology the background and experience our advisors bring to jivana is invaluable as we move our cancer therapies into clinical development and shape our drug delivery strategies”mr sage a registered patent attorney since  and founder of kalamazoo michbased hueschen  sage pllc specializes in advising innovator pharmaceutical dermatological and fine chemical companies in portfolio development prosecution management agency registration enforcement and partneringmr sage graduated from kalamazoo college with a ba in biology in  and from loyola university in chicago with a jd in  he started his career as a biochemist with the upjohn company conducting pharmacological research on putative alzheimer’s compoundsdr facchini is a boardcertified physician in interventional radiology dr facchini received his medical degree from loyola university stritch school of medicine he completed an internship in surgery at the university of chicago he completed residency training followed by a fellowship in interventional radiology at northwestern university he is certified by the american board of radiology and holds a certificate of added qualification in interventional radiologydr facchini is a member of several professional societies including the radiologic society of north america the american roentgen ray society the society of interventional radiology and the american medical associationhis special area of interest is minimally invasive image guided treatment of cancer interventional oncology he has authored and coauthored numerous articles scientific exhibits and book chapters he is actively involved in cancer research and founded the amita and advocate health systems y liver cancer treatment program one of the largest of its kind in the midwest dr facchini also has lead a research project to investigate new devices to repair spine fractures nonsurgically and another to repair aortic aneurysms dr facchini has been elected a fellow of the society of interventional radiology and served as development chair of its foundation dr facchini has recently joined btg plc in london as head of medical affairsjivana biotechnology develops rna interference rnai therapeutics to treat a wide range of cancers including breast ovarian liver lung thyroid and pancreatic by down modulating a specific gene product that prevents programmed cell death rnai is a mechanism present in living cells that inhibits the expression of a specific gene affecting production of a specific protein jivana’s rnaibased therapeutics help leverage this natural pathway of gene silencing contact information jivana biotechnology incsidney hoppscontactwwwjivanabiotechcom click here to view the list of recent press releases from jivana biotechnology inc promote your business affiliate program link to us email this page to a friend prcom contact us about us terms of use help science  jivana biotechnology jivana biotechnology home what we do pipeline who we are board of directors advisory committee consultants science rnaibased cancer therapeutics sirna embedded in the argonaut protein rna interference rnai is a naturally occurring biological process utilized by cells to regulate and silence gene expression at the rna level the discovery of rnai has been widely recognized as a groundbreaking achievement and represents a major new therapeutic advancement  with the discovery of rna interference rnai and its adoption as a new treatment paradigm undruggable intracellular targets are now accessible via rnai therapeuticsrnai has potency that goes far beyond the potency of traditional drug technologies enabling the effective use of oligonucleotidebased genedirected drugs in oncology for the first time  in addition rnai is gene specific allowing maximal therapeutic effect and minimal offtarget side effectsjivana biotechnology has exclusive global rights to a patent allowing us to deliver sirna against a key gene target that is overexpressed in hepatocellular carcinomas hcc  breast prostate pancreatic ovarian thyroid melanoma and numerous other cancersjivana biotechnology will deliver proprietary sirna molecules safely and efficiently to cancer cells using various lipid nanoparticle lnp formulations and self assembling drug conjugates made available by its drug delivery technology partners  the delivery formulations are specifically engineered to accumulate in tumors throughout the body and mediate efficient delivery of the sirnas to the rnai machinery in the cancer cell cytoplasmthe delivery particles are well tolerated and manufactured by jivana biotechnology’s partners using wellestablished gmp operations to ensure commercial consistency and scalabilityjivana biotechnology has entered pre clinical trials for hepatocellular carcinoma and breast cancer    ✕ what we do  jivana biotechnology jivana biotechnology home what we do pipeline who we are board of directors advisory committee consultants science we kill cancer cells but dont kill healthy cells rnaibased cancer drug development jivana biotechnology is a preclinicalstage biotechnology company bringing cancer therapeutics to market jivana biotechnology is a preclinical stage biotechnology company that down modulates an antiapoptotic protein in cancer cells through the process of gene silencing delivering packaged sirna and shrna to specific cells to prevent gene translation preventing production of our target protein triggers spontaneous cancer cell apoptosis and increases cancer cell sensitivity to a variety of chemotherapeutics and inhibitory drugsjivana is rapidly increasing its intellectual property portfolio by filing multiple combination therapy and dosing patents and filing for orphan drug designationsjivana therapies target greater than  billion in addressable markets including breast ovarian pancreatic liver lung thyroid blood cancers and moreusing targeted delivery vehicles to deliver our nucleotide sequence to the various tumor sites jivana biotechnology is poised to become a leader in oncologyfocused rnai therapeutics  relative levels of madd messenger rna expression in various types of cancer cells   ✕ jivana biotechnology  home jivana biotechnology home what we do pipeline who we are board of directors advisory committee consultants science the world will be a better place when we succeed   ✕ pipeline  jivana biotechnology jivana biotechnology home what we do pipeline who we are board of directors advisory committee consultants science   ✕ what we do  jivana biotechnology jivana biotechnology home what we do pipeline who we are board of directors advisory committee consultants science we kill cancer cells but dont kill healthy cells rnaibased cancer drug development jivana biotechnology is a preclinicalstage biotechnology company bringing cancer therapeutics to market jivana biotechnology is a preclinical stage biotechnology company that down modulates an antiapoptotic protein in cancer cells through the process of gene silencing delivering packaged sirna and shrna to specific cells to prevent gene translation preventing production of our target protein triggers spontaneous cancer cell apoptosis and increases cancer cell sensitivity to a variety of chemotherapeutics and inhibitory drugsjivana is rapidly increasing its intellectual property portfolio by filing multiple combination therapy and dosing patents and filing for orphan drug designationsjivana therapies target greater than  billion in addressable markets including breast ovarian pancreatic liver lung thyroid blood cancers and moreusing targeted delivery vehicles to deliver our nucleotide sequence to the various tumor sites jivana biotechnology is poised to become a leader in oncologyfocused rnai therapeutics  relative levels of madd messenger rna expression in various types of cancer cells   ✕ jivana biotechnology inc ceo and executives  bloomberg july    am et biotechnology company overview of jivana biotechnology inc snapshotpeople  overviewboard memberscommittees key executives for jivana biotechnology inc nameboard relationshipstitleagesidney hopps no relationshipschief executive officeradeeb alzoubi no relationshipscofounderbellur prabhakar no relationshipscofounder and chief scientific officer jivana biotechnology inc board members nameboard relationshipsprimary companyagethere is no board members data available jivana biotechnology inc executive committees committee namechairpersonboard relationshipsmembersthere is no committee data available data is at least as current as the most recent definitive proxy request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup ceo compensation in this industry  industry rangesalary kbonus ktotal short term compensation ktotal value of options mcompensation as of fiscal year jivana biotechnology inc ceo compensationindustry average industry executive changesmoleculin biotech inc announces resignation of jacqueline northcut as company’s board of directorsjuly    pm etbiocon limited announces the resignation of john mccallum marshall shaw as whole time directorjuly    pm etc therapeutics announces appointments to its scientific advisory boardjuly    pm etaduro biotech inc announces executive changesjuly    pm etintec pharma ltd promotes nadav navon to chief operating officerjuly    pm etsponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact jivana biotechnology inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close who we are  jivana biotechnology jivana biotechnology home what we do pipeline who we are board of directors advisory committee consultants science leading scientists and researchers and business professionals to support them   ✕   jivana biotechnology inc private company information  bloomberg july    am et biotechnology company overview of jivana biotechnology inc snapshot people company overview jivana biotechnology inc a preclinicalstage biotechnology company develops cancer therapeutics it develops gene silencing based therapeutics against geneticallydefined targets including liver breast pancreatic ovarian and thyroid cancers as well as leukemias and lymphomas jivana biotechnology inc was formerly known as mariam medical inc the company was incorporated in  and is based in river forest illinois  franklin avenueriver forest il united statesfounded in  phone  wwwjivanabiotechcom key executives for jivana biotechnology inc mr sidney hopps chief executive officer mr bellur prabhakar cofounder and chief scientific officer dr adeeb alzoubi cofounder compensation as of fiscal year  jivana biotechnology inc key developments jivana biotechnology inc presents at th annual conference biotech showcase jan dec   jivana biotechnology inc presents at th annual conference biotech showcase jan  venue hilton san francisco union square  ofarrell street san francisco ca  united states similar private companies by industry company name region n labs inc united states andme inc united states c tech corporation inc united states v biosciences inc united states bar biologics inc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact jivana biotechnology inc please visit wwwjivanabiotechcom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close jivana biotechnology inc is pleased to announce the addition of dr ajay maker to its advisory committee  oncology  cancer exploreuploadsign injoinclose user settings menuoptionsjoinsign inupload jivana biotechnology inc is pleased to announce the addition of dr ajay maker to its advisory committeeuploaded by prcomrelated interestsoncologycancerrna interferencenational cancer institutenational institutes of healthrating and stats document actionsshare or embed documentembeddescription dr maker brings surgical oncology experience with expertise in liver gallbladder colon pancreatic and other cancers to jivana biotechnologys advisory committeeview moredr maker brings surgical oncology experience with expertise in liver gallbladder colon pancreatic and other cancers to jivana biotechnologys advisory committeecopyright  all rights reservedflag for inappropriate content recommended documentsdocuments similar to jivana biotechnology inc is pleased to announce the addition of dr ajay maker to its advisory committeeplab  topicsby vicky waran rajarticuloby apiasparagusby santhikalyanadocuments about oncologyunited states v oncology associates th cir by scribd government docsunited states of america ex rel syed rahman md syed rahman md v oncology associates pc oncology services corporation douglas colkitt md jerome derdel md joanne russell oncology funding corporation stoneboro oncology associates pc warren oncology associates pc phoenixville oncology associates pc littlestown oncology associates pc lehighton oncology associates pc exton oncology associates pc bucks county oncology associates pc greenbelt cancer treatment center lp derdel randallstown oncology associates pc atlantic radiation oncology associates pc derdel union memorial oncology associates pc derdel riverside oncology associates pc derdel chesapeake oncology associates pc okeechobee oncology associates pa key west oncology associates pa tampa oncology associates pa treasure coast oncology associates pa lauderdale lakes oncology pa st lawrence oncology pc liberty oncology associates pc community radiation therapy by scribd government docsspotlight ep news august   no by spotlight ep newsmore from prcomscb international names michael varner as director of business developmentby prcomholistic wellness event in pacific palisades next monthby prcompropylon® announces launch of lwb a suite of legislative management applications to enhance capabilities and prioritize users’ needsby prcom screen reader compatibility informationdue to the method this document is displayed on the page screen readers may not read the content correctly for a better experience please download the original document and view it in the native application on your computer   kcvmbm cftolnbfafey cbl cs taomsoj tf mbbfublo tno mjjctcfb fg jr mkmyimhor tf cts mjvcsfry lfiicttoo  jr imhor rcbes sureclma fblfafey oxporcoblo wctn oxportcso cb acvor emaaamjjor lfafb pmblromtcl mbj ftnor lmblors tf kcvmbm cftolnbfafeys mjvcsfry lfiicttoo lnclmef ca imrln   tplfi kcvmbm cftolnbfafey cbl cs paomsoj tf mbbfublo tno mjjctcfbfg jr mkmy imhor tf cts mjvcsfry lfiicttoouo mro tnrcaaoj wctn tncs mjjctcfb tf fur mjvcsfry lfiicttoo smcj cj nfpps proscjobt mbj lncog oxolutcvo fggclor fg kcvmbm cftolnbfafey zno mlherfubj mbj oxporcoblo jr imhor rcbes tf kcvmbm cscbvmaumao ms wo ifvo fur lmblor tnormpcos cbtf lacbclma jovoafpiobt mbj snmpo fur jrue joacvorystrmtoecos’jr imhor cs m sureclma fblfafecst wctn fmrj lortcgclmtcfb cb eoborma sureory ncs oxportcso cblaujostromtcbe obceb mbj imacebmbt jcsomsos fg tno acvor cao jults emaaamjjor mbj pmblroms ms woaa ms lfafbmbj ftnor emstrfcbtostcbma lmblors ioambfim mbj smrlfim no kfcboj tno jcvcscfb fg ureclma fblfafeymbj tno jopmrtiobt fg iclrfcfafey mbj ciiubfafey mt tno bcvorscty fg caacbfcs mt lnclmef mgtorlfipaotcbe m goaafwsncp cb sureclma fblfafey wctn m gflus upfb nopmtfpmblromtfcacmry sureory mtioifrcma afmbhottorcbe lmblor lobtor mbj m goaafwsncp cb zuifr ciiubfafey mbj ureclmafblfafey mt tno bmtcfbma lmblor cbstctuto jr imhor lmros gfr pmtcobts ms pmrt fg m iuatcjcslcpacbmry tomifg iojclma fblfafecsts rmjcmtcfb fblfafecsts emstrfobtorfafecsts mbj rmjcfafecsts wnf spolcmaczo cbtromtcbe pmtcobts wctn tnoso spolcgcl lmblorsjr imhor ermjumtoj grfi rfwb bcvorscty wctn nfbfrs cb gcbo mrts mbj cfafey znoromgtor no obrfaaojcb tno smao lnffa fg iojclcbo mbj wms soaoltoj tf obtor tno mscl lcoblo posomrln zrmcbcbe goaafwsncpwnoro no wms mwmrjoj tno iojclma lnfamrs mwmrj grfi tno miorclmb jcmotos mssflcmtcfb mbj tnomssflcmtcfb gfr mlmjoicl ureorybfvmrtcs posomrln mwmrj pfb obtorcbe tno sureclma roscjoblytrmcbcbe prfermi mt nmrvmrj bcvorsctys rcenmi mbj ufiobs nfspctma no nmj maromjy lnfsob tfpursuo m lmroor cb sureclma fblfafey mbj wms mlloptoj cbtf tno pfstjfltfrma sureclma fblfafey goaafwsncpprfermi ubjor jr tovob pfsobore cb tno ureory rmbln fg tno bmtcfbma lmblor cbstctuto mt tnobmtcfbma cbstctutos fg nomatn blcbcn znoromgtor no wobt fb tf lfipaoto m sureclma fblfafeygoaafwsncp mt tno ioifrcma afmbhottorcbe lmblor lobtorjr imhor sorvos ms m rovcowor gfr iuatcpao sureory mbj slcobtcgcl kfurbmas mbj cs m ioior fg iuatcpaomlmjoicl mbj slcobtcgcl sflcotcos cblaujcbe tno flcoty fg ureclma fblfafeys emstrfcbtostcbma fblfafeyufrhcbe erfup tno miorclms nopmtfpmblromtfcacmry mssflcmtcfbs rosomrln lfiicttoo mbj tnomssflcmtcfb gfr mlmjoicl ureorys aomjorsncp lfiicttoo no lurrobtay cs jcroltfr fg ureclma fblfafeygfr tno lrotclfs lmblor lobtor mbj jcroltfr fg ureclma posomrln gfr tno bcvorscty fg caacbfcsiotrfpfactmb erfup nfspctmas eoborma ureory poscjobly zrmcbcbe trfermi lurrobtay no sorvos ms tnoprcblcpma cbvostcemtfr fb m iuatcyomr gojorma rosomrln ermbt grfi tno bmtcfbma lmblor cbstctutobmtcfbmacbstctutos fg nomatn tf stujy tno ciiubfcfafey fg ec lmblors tmeo tplfi tross poaomso jcstrcutcfbzoris fg so   kcvmbm cftolnbfafey jovoafps pbm cbtorgoroblo pbmc tnormpoutcls tf tromt m wcjo rmbeo fg lmblorscblaujcbe romst fvmrcmb acvor aube tnyrfcj mbj pmblromtcl y jfwb ifjuamtcbe m spolcgcl eobo prfjulttnmt provobts prfermiioj loaa jomtn pbmc cs m iolnmbcsi prosobt cb acvcbe loaas tnmt cbnccts tnooxprosscfb fg m spolcgcl eobo mggoltcbe prfjultcfb fg m spolcgcl prftocb kcvmbms pbmcmsoj tnormpoutclsnoap aovormeo tncs bmturma pmtnwmy fg eobo scaoblcbe tmeo tplfi tross poaomso jcstrcutcfbzoris fg so sign up to vote on this titleusefulnot usefulclose dialogare you surethis action might not be possible to undo are you sure you want to continuecancelokclose dialogget the full title to continueget the full title to continue reading from where you left off or restart the previewrestart preview  fiercebiotech skip to main content twitter linkedin search  any ebookebriefeventexecutive summaryjobmultimediapaid marketplaceresearchsurveyvideowebinarwhitepaper  any homepagebiotechrddealsregulatoryventure capitaloutsourcingpartneringfinancialsresearchrddealsregulatorypersonalized medicineitdealsrddata managementregulatorygenomicsdigitalsocial mediacrorddealsregulatorypartneringfinancialsmanufacturingmedtechdealsfinancialsrdregulatory sort by published date order oldestnewest webinarexploring adc pharmacokinetics using qsp modeling strategiesseptember    pm et  am pt  presented by applied biomath the pharmacokinetics pk of adc therapeutics typically show a discrepancy between the pk of total antibody and that of conjugated antibody carrying one or more payload molecules this will present how quantitative systems pharmacology modeling approaches provide biological insights into the impact of drugtoantibody ratio and the resulting changes in molecular properties on overall pk and relative payload disposition as observed in preclinical and clinical studies register now more info webinarperkinelmer signals™ notebook lightningfast collaboration and searchseptember   pm gt  am et  am pt  presented by perkinelmer perkinelmer signals™ notebook is the first electronic laboratory platform built with the latest technologies designed to achieve both the strategic objective of better decision support as well as the tactical objectives of improved collaboration compliance and operational efficiency in this webinar we will discuss industry trends relating to these objectives and perkinelmer’s corresponding distinctive solution  register now   more info webinaraccelerate clinical trials with rapid application developmentaugust     pm et   am pt  presented by salesforce clinical trials are at a crossroads biopharmaceutical companies must accelerate the development and approval of tailored therapeutics but legacy clinical it infrastructure makes it difficult to keep up this webinar will highlight how life science companies are building connected rd applications using an agile intelligent platform that connects key stakeholders including sponsors cros sites and subjects learn from customer success stories and live demonstrations and see how you can apply this approach to turbocharge your own clinical programs register now more info webinaraccelerating clinical trials through adaptive designsaugust    pm etam pt  presented by cardinal health for biopharmaceutical developers designing a time and costeffective clinical strategy from product inception to regulatory approval is essential for meeting earlyphase clinical trial objectives this interactive webinar will provide the framework for scientifically robust and efficient earlyphase clinical drug development and highlight working with crossfunctional teams and developing appropriate operational infrastructure for all stakeholders register now more info webinarbring your life sciences content management strategy into the digital ageaugust    pm et  am pt  presented by medidata solutions the life sciences industry is undergoing a digital transformation as legacy it systems move into the cloud and cohesive transition strategies are required whether you’re in quality control clinical operations it regulatory compliance or manage another area of the trial join medidata and box explore how to build a total regulated and nonregulated content management strategy to match todays unique challenges including implementing technology via a single userfriendly platform register now more info webinarconnecting the drug development journey with datadriven insightsjuly    am et  am pt  presented by parexel while biopharmaceutical companies face challenges in generating and integrating meaningful insights that drive timely and actionable decisions aggregating and leveraging the right data to drive value requires a broad range of services working together to generate insights across the entire drug development spectrum hear parexel experts derive datadriven insights and how these insights can benefit many essential drug development areas register now more info webinarhow modern quality systems are transforming change managementnow ondemand  presented by veeva assessing impact and creating and executing a change plan are difficult with global stakeholders and multitude of systems during this webinar learn frameworks and best practices for transforming change management register now more info webinaraccelerate your speed to market new options for generic drug packaging  deliverynow available ondemand  presented by west pharmaceutical services quality speed simplicity learn how a new elastomeric closure formulation turnkey extractables and leachables package and a flexible supply can help generics manufacturers make the move to market join this webinar with west experts and learn about generics market trends and acceltra™ brand program attributes that address generic injectable drug manufacturer issues and ensure a fast move to market register now more info videovideo api discussion with dr robert dewit ceo of mpi researchpresented by mpi research fiercebiotech interviews dr dewit to discuss a common cause for drug development delays and strategies to avoid these costly setbacks  click to watch the interview now more info webinarleveraging real world data to streamline clinical trialsnow available ondemand  presented by trinetx inc join this webinar to learn how real world data is transforming the way biopharma cros and study sites navigate obstacles in drug development the impact of real world data on clinical trials and the appropriate use cases to incorporate real world data in the planning and execution of clinical trials register now more info popular content astrazenecas immunooncology combo fails crucial mystic trial in lung cancer jul   glaxosmithkline stops development of  pipeline prospects mulls sale of rare disease unit as new ceo walmsley makes her mark jul   alexion scraps moderna pact as new ceo cleans house jul   how parp inhibitors might prove useful in more than just brca cancers jul   lilly puts twothirds of midphase cancer pipeline up for sale in major shakeup of rd priorities jul   newsletter subscription  fiercebiotech skip to main content twitter linkedin search newsletter subscription   popular content astrazenecas immunooncology combo fails crucial mystic trial in lung cancer jul   alexion scraps moderna pact as new ceo cleans house jul   glaxosmithkline stops development of  pipeline prospects mulls sale of rare disease unit as new ceo walmsley makes her mark jul   how parp inhibitors might prove useful in more than just brca cancers jul   astellas winds down agensys turning its back on antibodydrug conjugate research jul   microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft  fiercebiotech skip to main content twitter linkedin search  any homepagebiotechrddealsregulatoryventure capitaloutsourcingpartneringfinancialsresearchrddealsregulatorypersonalized medicineitdealsrddata managementregulatorygenomicsdigitalsocial mediacrorddealsregulatorypartneringfinancialsmanufacturingmedtechdealsfinancialsrdregulatory sort by published date order oldestnewest eventdon’t miss the industry’s premier io conference – the immunooncology summitaugust   september    boston ma  sponsored by cambridge healthtech institute join  international delegates for this weeklong  conference summit topics include immunotherapy discovery biomarkers and translational oncology cancer vaccines oncolytic viruses and advances in synthetic biology techniques register now more info eventfiercebiotech nd drug development forumseptember    boston ma  sponsored by fiercebiotech join  csuite biotech executives at the unmatched educational venue for drug development professionals this event will cover the greatest partnership challenges that biotech companies face throughout the entire product and corporate development cycle to learn more or register click here more info eventdrug development boot camp® november    boston ma  sponsored by harvard university otd and speid  associates inc intensive training in drug development for experienced researchers and drug developers if you are working in unmet medical need areas and are not afraid of a challenging and intense training program this is the training program you have been looking for  people from large pharma biotech nihnci dod academia and government can register now more info popular content astrazenecas immunooncology combo fails crucial mystic trial in lung cancer jul   glaxosmithkline stops development of  pipeline prospects mulls sale of rare disease unit as new ceo walmsley makes her mark jul   alexion scraps moderna pact as new ceo cleans house jul   how parp inhibitors might prove useful in more than just brca cancers jul   lilly puts twothirds of midphase cancer pipeline up for sale in major shakeup of rd priorities jul   jivana biotechnology inc announces additions to its advisory committee  benzinga benzinga benzinga pro marketfy financial data  apis fintech awards premarket prep membership is freewhat are you waiting for sign up now username username availableusername taken email email availableemail taken password leave blank or free account login click here to access your premium account username or email password or forgot password looking for  click here contribute login sign up benzinga  feed your mind homebest of benzinga careers about contact us partners benzinga fintech awards newsearnings guidance dividends ma buybacks legal interviews management retail sales offerings ipos insider trades biotechfda marketspremarket after hours movers forex commodities options binary options bonds futures global economics previews reviews smallcap ratingsanalyst color downgrades upgrades initiations price target ideaslong ideas short ideas technicals from the press jim cramer rumors etfs techstartups fintech personal finance marketfy benzinga pro market overview tickersarticleskeywordssearch by keywordgooglecse jivana biotechnology inc announces additions to its advisory committee prcom    april   am   comments share chicago il april   prcom jivana biotechnology inc is pleased to announce the addition of patrick sage and dr frank facchini to its advisory committee we are thrilled with this addition to our advisory committee said sid hopps president and chief executive officer of jivana biotechnology the background and experience our advisors bring to jivana is invaluable as we move our cancer therapies into clinical development and shape our drug delivery strategies mr sage a registered patent attorney since  and founder of kalamazoo michbased hueschen  sage pllc specializes in advising innovator pharmaceutical dermatological and fine chemical companies in portfolio development prosecution management agency registration enforcement and partnering mr sage graduated from kalamazoo college with a ba in biology in  and from loyola university in chicago with a jd in  he started his career as a biochemist with the upjohn company conducting pharmacological research on putative alzheimers compounds dr facchini is a boardcertified physician in interventional radiology dr facchini received his medical degree from loyola university stritch school of medicine he completed an internship in surgery at the university of chicago he completed residency training followed by a fellowship in interventional radiology at northwestern university he is certified by the american board of radiology and holds a certificate of added qualification in interventional radiology dr facchini is a member of several professional societies including the radiologic society of north america the american roentgen ray society the society of interventional radiology and the american medical association his special area of interest is minimally invasive image guided treatment of cancer interventional oncology he has authored and coauthored numerous articles scientific exhibits and book chapters he is actively involved in cancer research and founded the amita and advocate health systems y liver cancer treatment program one of the largest of its kind in the midwest dr facchini also has lead a research project to investigate new devices to repair spine fractures nonsurgically and another to repair aortic aneurysms dr facchini has been elected a fellow of the society of interventional radiology and served as development chair of its foundation dr facchini has recently joined btg plc in london as head of medical affairs jivana biotechnology develops rna interference rnai therapeutics to treat a wide range of cancers including breast ovarian liver lung thyroid and pancreatic by down modulating a specific gene product that prevents programmed cell death rnai is a mechanism present in living cells that inhibits the expression of a specific gene affecting production of a specific protein jivanas rnaibased therapeutics help leverage this natural pathway of gene silencing contact information jivana biotechnology inc sidney hopps  contact via email wwwjivanabiotechcom read the full story here httpwwwprcompressrelease press release distributed by prcom view comments and join the discussion   view the discussion thread newsletter  alerts become a wallstreet wizard market in  minutes everything you need to know about the market  quick  easy daily analyst rating a summary of each day’s top rating changes from sellside analysts on the street fintech focus yesterday’s biggest gainers and losers as well as  stocks to keep an eye on for today terms  conditions thank you for registering for benzinga’s newsletters and alerts • the daily analysts ratings email will be received daily between am and am • the market in  minutes email will be received daily between am and am • the fintech focus email will be received every friday between pm and pm if you have any questions as it relates to either of the three newsletters please feel free to contact us at zing trending recent  pme ffiv  stocks moving in thursdays premarket session  cxw fslr  stocks moving in fridays premarket session  azn pfe why is astrazeneca sinking today  amzn googl the jpmorgan midday note that might have s  tsla teslas breakout will take longer  nue x trump comments on trade caused th  unm bud earnings scheduled for ju  dvax dynavax gets  fda vote for hepatitis b vaccine  algn inside align technologys q beat and raise teen segment could see  ua kn benzingas option alert recap from july   pfe atvi earnings watch apple tesla pfizer activisionblizzard   things you may not know about anthony scaramucci  capr nvax we spoke with the experts and learned the secr  mo gnc midafternoon market update cyberoptics view upcoming earnings ratings dividend and economic calendars benzinga is a fastgrowing dynamic and innovative financial media outlet that empowers investors with highquality unique content popular channelsanalyst ratings be your own boss etfs economics forex hot news options press releases startups tech tools  featuresaffiliate program premarket prep feeds news widget real time feed sitemap submit news tips about benzingaabout us licensing and apis apps ios and android fintech awards blog syndication in the news careers service status contact us disclaimer privacy policy terms and conditions benzinga partners    zing  copyright benzinga